What is the main purpose of this 8-K filing?

This 8-K filing by Pfizer Inc. is to formally announce the execution of a merger agreement with Allergan plc, signaling a significant corporate development. It provides initial details and directs investors to upcoming, more comprehensive filings for further information on the transaction.

What are the next steps for this proposed merger?

Following this announcement, Allergan plc will file a registration statement on Form S-4 with the SEC. This filing will include a Joint Proxy Statement/Prospectus, which will be mailed to shareholders of both Pfizer and Allergan and will contain essential details about the transaction and how shareholders can vote on it.

What risks are associated with this merger announcement?

The filing highlights several risks, including the potential failure to obtain necessary regulatory and shareholder approvals, the possibility of conditions being imposed on approvals that could negatively impact the combined company, the risk of termination of the merger agreement, negative impacts on stock prices, failure to realize expected synergies, and potential litigation or regulatory actions.

Where can I find more detailed information about the merger?

More detailed information will be available in the Joint Proxy Statement/Prospectus to be filed by Allergan on Form S-4 and subsequently mailed to shareholders. Investors can also find information on the SEC's website (www.sec.gov) and by contacting the investor relations departments of Pfizer and Allergan.

PFE 8-K SEC Disclosure — Nov 23, 2015

Summary

Pfizer Inc. has filed a Form 8-K on November 23, 2015, to announce the execution of an Agreement and Plan of Merger with Allergan plc. This significant event outlines the framework for a merger between the two pharmaceutical giants. The filing also includes a joint press release and supplemental investor presentation providing further details on the proposed transaction. Investors should note that this announcement is a preliminary step, and further filings, including a registration statement on Form S-4 containing a Joint Proxy Statement/Prospectus, will be made with the SEC. These documents will contain crucial information for shareholders of both companies regarding the merger's terms, implications, and the voting process. This transaction is positioned as a strategic move by Pfizer, with the accompanying investor presentation likely detailing the anticipated benefits, financial projections, and rationale behind the merger. However, the company explicitly cautions that the merger is subject to various conditions, including regulatory and shareholder approvals, and carries inherent risks. Investors are urged to review all forthcoming SEC filings for a comprehensive understanding of the transaction and to make informed investment decisions. The filing serves as an initial notification to the market about this material development.

Key Highlights

1Pfizer Inc. and Allergan plc have entered into an Agreement and Plan of Merger, dated November 22, 2015.
2The 8-K filing serves as an announcement of this material event, triggering reporting obligations.
3A joint press release from Pfizer and Allergan, dated November 23, 2015, is attached as an exhibit.
4Supplemental investor presentation materials regarding the proposed transaction are also provided as an exhibit.
5The transaction is subject to shareholder and regulatory approvals, as well as other closing conditions.
6Further detailed information will be available in a forthcoming registration statement on Form S-4, including a Joint Proxy Statement/Prospectus.
7Pfizer includes a cautionary statement regarding forward-looking statements and the inherent risks associated with the proposed merger.

PFIZER INC 8-K Report, Corporate Update (Nov 23, 2015)

Summary

Key Highlights

Frequently Asked Questions